Orasis Files BESKA Presbyopia NDA in Australia
Orasis BESKA TGA Australia NDA for adult presbyopia is now under review. Orasis and Aspen Pharmacare Australia said on July 15, 2026 that Aspen filed the first ex-U.S. application for the pilocarpine 0.4% eye drop marketed as QLOSI in the United States.
Contents9 sections
Key Takeaways
- Aspen submitted a TGA NDA for BESKA (pilocarpine HCl 0.4%) for adult presbyopia.
- Filing is the first ex-U.S. regulatory submission for the QLOSI / BESKA franchise.
- NEAR-1 and NEAR-2 Phase 3 trials (>600 adults) underpin the dossier.
- Product is not TGA-approved yet; Aspen would commercialize in Australia if cleared.
BESKA Australia filing at a glance
| Field | Detail |
|---|---|
| Product | BESKA (pilocarpine hydrochloride ophthalmic solution) 0.4% |
| U.S. brand | QLOSI |
| Sponsors | Orasis Pharmaceuticals; Aspen Pharmacare Australia (filer/commercial) |
| Regulator | Australia TGA |
| Action | NDA submitted / accepted for review (announced July 15, 2026) |
| Indication sought | Presbyopia in adults |
| Pivotal evidence | NEAR-1 and NEAR-2 Phase 3 |
What was filed?
Aspen lodged an NDA seeking Australian approval of a preservative-free, low-dose pilocarpine drop designed to improve near vision via pupil modulation (a pinhole / depth-of-field effect) without compromising distance acuity. Orasis already markets the same formulation in the U.S. as QLOSI.
Source: Orasis and Aspen's July 15 PR Newswire NDA announcement. TGA's role in prescription medicine evaluation is described on TGA's medicines pages.
What do NEAR-1 and NEAR-2 claim?
- More than 600 adults with presbyopia across two pivotal Phase 3 studies
- Day 8 primary success on ≥3-line DCNVA gain without ≥1-line distance loss
- Most common treatment-related AEs in single digits: headache 6.8%, instillation site pain 5.8%
Trial registrations and protocols for the NEAR program can be searched on ClinicalTrials.gov. Australian clinicians should treat U.S. QLOSI experience as supportive context only until a local ARTG entry and Product Information exist.
Why does APAC care about this filing?
Presbyopia affects roughly two billion people globally and typically begins after age 40. Many patients still rely on readers or refractive surgery. A pharmacologic drop expands options if TGA concludes the benefit-risk is acceptable for Australian use. Aspen's Asia-Pacific commercial infrastructure is the intended bridge from U.S. approval to a first ex-U.S. launch market.
Submission is not approval. Review questions may cover miotic night-vision effects, headache rates, preservative-free manufacturing controls, and how the Australian label should differ from U.S. labeling. Aspen has spoken about preparing for approval and launch timing after review rather than guaranteeing a calendar date.
What remains uncertain?
TGA decision timing, PBS listing prospects, and final Australian Product Information wording are unknown. Competitive miotic and other pharmacologic presbyopia programs could change the commercial window. Cross-border importation of U.S. QLOSI is a separate regulatory issue and should not be assumed from this NDA filing alone.
Related NovaPharma coverage
- TGA expands SPEVIGO for adolescent GPP care
- TGA Digital Mental Health Tools Consultation Update
- Asia-Pacific medical radioisotopes supply TGA
Frequently Asked Questions
What did Orasis and Aspen submit in Australia?
On July 15, 2026, Orasis Pharmaceuticals and Aspen Pharmacare Australia said Aspen submitted a New Drug Application to Australia's Therapeutic Goods Administration for BESKA (pilocarpine hydrochloride ophthalmic solution) 0.4% for the treatment of presbyopia in adults. BESKA is the Australian trademark for the product known as QLOSI in the United States.
What clinical data support the TGA filing?
The companies said the NDA is supported by Phase 3 NEAR-1 and NEAR-2 trials in more than 600 adults with presbyopia. Both trials met primary and key secondary endpoints on Day 8 for a three-line or greater gain in distance-corrected near visual acuity without a one-line or greater loss in distance acuity. Common treatment-related adverse events included headache (6.8%) and instillation site pain (5.8%).
Is BESKA approved in Australia?
No. Aspen said the NDA has been submitted and accepted for TGA review, but BESKA is not yet approved in Australia. Aspen will handle distribution and marketing if approved; the companies have discussed preparation for a potential launch after review.
Primary Sources
Regulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for BESKA.
Unlock full calendar →Entity graph
Continue Exploring
Open the drugs, companies, and topics behind this story.
This article follows our editorial standards. Report a correction via editorial contact.
